To date, transcriptional dysregulations of CD300s, especially CD300A and CD300LF, have been reported mostly in patients with hematological malignancies, such as ALL, AML, and DLBCL.26, 27, 28, 29, 53, 54. Here, CD300A is linked to hematologic disorder.